02:33 , Jul 13, 2019 |  BioCentury  |  Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

The performance of 1H19 IPOs point toward a continuation of a dual-class system where biotechs backed by deep-pocketed VCs and crossover investors can tap the public market at will and generate stronger after-market performance than...
16:55 , Apr 19, 2019 |  BC Week In Review  |  Company News

BioSense gets Asia rights to Rexahn's pancreatic cancer therapy

BioSense gained exclusive rights to develop and commercialize Rexahn's RX-3117 to treat and prevent pancreatic cancer in Singapore, China, Hong Kong, Macau and Taiwan. Rexahn Pharmaceuticals Inc. (NYSE-A:RNN) will receive $3 million up front and...
21:19 , Mar 22, 2019 |  BC Extra  |  Company News

Management tracks: Mirum, Novocure

Mirum said Mike Grey has stepped down as CEO but will remain executive chairman. Mirum Pharmaceuticals Inc. (San Francisco, Calif.) promoted President Chris Peetz to CEO. Peetz is also a director. Mirum launched in 2018...
18:36 , Aug 9, 2017 |  BC Innovations  |  Distillery Therapeutics

Pulmonary

INDICATION: Acute lung injury Patient sample and mouse studies suggest inhibiting HIF1A could help treat acute lung injury (ALI). Levels of HIF1A in lung tissue samples from patients with idiopathic pulmonary fibrosis (IPF) and a...
05:05 , Jun 16, 2017 |  BC Week In Review  |  Financial News

Rexahn raises $10M in registered direct offering

On June 12, cancer company Rexahn Pharmaceuticals Inc. (NYSE-M:RNN) raised $10 million through the sale of 3 million units at $3.30 in a registered direct offering. Each unit comprises a share and a five-year warrant...
01:05 , Apr 21, 2017 |  BC Innovations  |  Product R&D

Making marks at AACR

Biomarkers that could stratify patients, point to treatment combinations or predict toxicity were a major part of the conversation at this year’s AACR conference, where they emerged as potential difference makers for a range of...
17:39 , Mar 3, 2017 |  BC Week In Review  |  Clinical News

Supinoxin: Ph IIa started

Rexahn began an open-label, U.S. Phase IIa trial to evaluate Supinoxin in up to 50 patients who have failed prior therapies. Rexahn Pharmaceuticals Inc. (NYSE-M:RNN), Rockville, Md.  Product: Supinoxin (RX-5902)   Business: Cancer   Molecular...
07:00 , Oct 17, 2016 |  BioCentury  |  Product Development

Yes we PanCAN

A major goal of a new multidrug platform study organized by the Pancreatic Cancer Action Network is to meet patients' needs better than traditional trials do. Among other things, that means accepting patients who have...
07:00 , Oct 17, 2016 |  BC Week In Review  |  Clinical News

RX-3117: Phase Ib/IIa data

Data from 9 evaluable patients with relapsed or refractory metastatic pancreatic cancer in stage 1 of an open-label, U.S. Phase Ib/IIa trial showed that once-daily 700 mg oral RX-3117 given 5 times per week for...
07:00 , Sep 19, 2016 |  BC Week In Review  |  Financial News

Rexahn completes direct public offering

Rexahn Pharmaceuticals Inc. (NYSE-M:RNN), Rockville, Md.   Business: Cancer, Neurology, Genitourinary   Date completed: 2016-09-14   Type: Direct public offering   Raised: $6 million   Units: 24 million   Price: $0.25 (unit)   Shares after...